Results 11 to 20 of about 17,302 (216)
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was
Daisuke Okamura +9 more
doaj +2 more sources
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers +4 more
doaj +2 more sources
Azacitidine-induced bullous pemphigoid-like localized toxic reaction [PDF]
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation ...
Rodrigo Brêtas Emerich Nogueira +7 more
doaj +3 more sources
Safety and efficacy of azacitidine in myelodysplastic syndromes
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil +2 more
doaj +1 more source
Real‐world study of the use of azacitidine in myelodysplasia in Australia
Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation.
Anoop Enjeti +7 more
doaj +2 more sources
Azacitidine and venetoclax are important anti-neoplastic agents used in the treatment of acute myeloid leukemia. Azacitidine has been implicated to cause nonhepatic ischemic injury. Here we report a case of severe, short latency drug-induced liver injury
Dilara Hatipoglu MD +3 more
doaj +2 more sources
Cytomegalovirus Colitis Following Azacitidine Therapy [PDF]
The present report describes the first recognized case of cytomegalovirus (CMV) colitis following azacitidine therapy. A 66-year-old woman with myelodysplastic syndrome developed CMV colitis, which responded to treatment with ganciclovir.
Rajal Khan +6 more
doaj +2 more sources
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
KS Götze, C Müller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universität München, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders ...
KS Götze +2 more
doaj +1 more source
Thrombocytopenia between azacitidine monotherapy vs azacitidine combination.
Thrombocytopenia between azacitidine monotherapy vs azacitidine combination.
Romina Brignardello-Petersen (814592) +7 more
core +1 more source
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. [PDF]
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS).
RIVELLINI F +10 more
core +1 more source

